Second drug boosts triptan efficacy for migraine
|
Tweet
|
|
Adding trimebutine to rizatriptan therapy appears to hasten the resolution of migraine attacks, according to a study.
Trimebutine is “well-tolerated” and “may represent an additional resource in the available arsenal to treat migraine attacks,” investigators say.
“In an era of potential new agents for the acute treatment of migraine, raising the efficacy of already safe and available drugs through the combination of traditional medications may represent an attractive option,” they write in a report in the journal Cephalagia.
Delayed gastric emptying, or “gastric paralysis,” is common during migraine attacks and can delay the onset of action for drugs taken by mouth, Dr. Abouch V. Krymchantowski, from Hospital Pasteur in Rio de Janeiro, Brazil, and colleagues explain.
This is particularly relevant for triptans, which seem to work best during the early stages of an attack.
Therefore, use of a “gastrokinetic” agent, such as trimebutine that helps regulate movement of contents in the gastrointestinal tract, could potentially improve the efficacy of triptan therapy. Trimebutine is often used to treat irritable bowel syndrome (spastic colon).
In a crossover study, the investigators assessed the outcomes of 40 patients who were randomized to treat two consecutive migraine attacks with rizatriptan (10 mg) plus either trimebutine (200 mg) or placebo.
A total of 64 attacks were treated with each of the regimens.
Within 1 hour of dosing, 30 (46.8 percent) of the attacks treated with the two-drug combination had resolved compared with just 8 (12.5 percent) of the attacks treated with rizatriptan alone, a significant difference. At 2 hours, the difference persisted with corresponding resolution rates of 73.4 percent and 31.2 percent.
Rizatriptan plus trimebutine was also significantly better than rizatriptan alone at resolving the nausea and photophobia accompanying the migraines.
Cephalalgia July 2006.
Revision date: July 8, 2011
Last revised: by Andrew G. Epstein, M.D.
| RELATED STORIES: | ||
| Comments | [ + Post Your Own ] |
Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.
There are no comments for this entry yet. [ + Comment here + ]
We are pleased to let readers post comments about an article. Please increase the credibility of your post by including your full name and email.
All comments are reviewed by our editors before they are posted on the site. Just keep it clean, kids.
- Full Story - - »»»
State tobacco prevention funding lacking
- Full Story - - »»»
C-Section Babies Face High Obesity Risk
- Full Story - - »»»
Scientists turn skin cells into beating heart muscle
- Full Story - - »»»
Too many people get angioplasties, study suggests
- Full Story - - »»»
Comparing Birth Control Pill Types
- Full Story - - »»»
Viewers’ family background affects how they react to MTV shows ‘16 and Pregnant,’ ‘Teen Mom’
- Full Story - - »»»

